Proponents argue that novel biomarker tests can detect Alzheimer's at early stages, allowing timely treatments. In contrast, critics warn of misdiagnosis risks for asymptomatic individuals.
There's a risk of misunderstanding and distress that individuals who are asymptomatic will have if we tell them they have Alzheimer's, whereas nothing will happen in their lifetime in a majority of cases,
It's this confluence of the possibility of widespread clinically available, accurate diagnosis with the ability to do something about the disease that prompted us to update the criteria.
Collection
[
|
...
]